Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma

The JULIET phase 2 trial evaluated a single infusion of tisagenlecleucel in adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The objective of the current analysis was to evaluate patient-reported health-related quality of life (HRQoL) with a median follow-up of 19...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Main Authors: Maziarz, Richard T., Waller, Edmund K., Jaeger, Ulrich, Fleury, Isabelle, McGuirk, Joseph, Holte, Harald, Jaglowski, Samantha, Schuster, Stephen J., Bishop, Michael R., Westin, Jason R., Mielke, Stephan, Teshima, Takanori, Bachanova, Veronika, Foley, Stephen R., Borchmann, Peter, Salles, Gilles A., Zhang, Jie, Tiwari, Ranjan, Pacaud, Lida B., Ma, Qiufei, Tam, Constantine S.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2020
Assuntos:
Immunobiology and Immunotherapy
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7042998/
https://ncbi.nlm.nih.gov/pubmed/32074277
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001026
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares